Drug Trial Radar · NCT05130021
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
130
Planned (sponsor's estimate)
Start
Jan 31, 2022
Primary completion
May 30, 2022
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.
Conditions
- Metastatic Colorectal Cancer
Interventions
MAX-40279-01Drug
MAX-40279-01 50mg/70mg
regorafenibDrug
regorafenib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease control rate (DCR)[Part 1]Time frame: Through study Part 1 completion, an average of 6 months
- progress free survival(PFS)[Part 2]Time frame: Through study Part 1 completion, an average of 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.